Biotechnology Opportunities

An Expert's View about Human Health Services in Australia

Last updated: 12 Apr 2011

Australia has a thriving biotechnology sector including around 450 companies and a world class scientific, medical and agricultural research base.

Sector briefing Biotechnology Opportunities in AUSTRALIA Why Australia? Australia is the leading location of Biotechnology in the Asia Pacific region. Australia has a thriving biotechnology sector including around 450 companies and a world class scientific, medical and agricultural research base. th Australia is ranked the 6 largest biotechnology industry in the world behind the US, UK, Canada, Germany and France. With beneficial exchange rates, a booming economy and proximity to the emerging markets of the Asia Pacific region, there has th never been a better time to do business in ?Australia is the 6 largest Australia. biotechnology market in the world and the leading location of Find general information on the Australian biotechnology in the Asia Pacific market conditions on UKTI?s website. The region.? Doing Business Guide for Australia gives an overview of Australia?s economy, business culture, potential opportunities and an introduction to other relevant issues. UK Trade & Investment Sector briefing: Biotechnology opportunities in AUSTRALIA medical research institutes, eleven teaching Opportunities hospitals and 9 universities. Melbourne joins London and Boston as the only three cities in Opportunities are widely available in Australia the world with two universities in the global top for British companies; 20 biomedical rankings. For biotechnology and pharmaceutical companies looking to partner with world- As part of initiatives to encourage the growth leading research institutions, license in projects of the biotechnology industry Victoria has at pre-clinical or phase 2 stages or license out developed a number of Biotechnology Precincts technology particularly in the oncology and with shared infrastructure between Universities infectious disease space; Research Hospitals and private companies to For companies looking to market services in encourage sharing of facilities and expertise. drug discovery, development, clinical trials and These include: contract manufacturing. The Bio21 Cluster Industry Overview & Characteristics The Bio21 Cluster links 22 research CSL, based in Melbourne, is Australia?s largest organisations to support shared infrastructure biotechnology player and currently the 4th and expertise in biotechnology. The project largest biotech company in the world based on has established the Bio21 Institute at the sales and has a market cap around $20 billion. University of Melbourne and six collaborative CSL?s key areas of expertise include blood infrastructure projects providing access to plasma products, vaccines, antibodies and platform technologies such as high-throughput recombinant biotechnology. screening, informatics and protein crystallisation. It is also home to the Victorian Major recent activity in the Australian biotech Life Sciences Computation initiative. market has included US company Cephalon?s $320 million takeover of Arana Therapeutics, Parkville Precinct Danish company Leo Pharma acquiring Peplin The Parkville Precinct is the major precinct in for $307 million, Acrux?s $600 million licensing Australia for medical and bioscientific research, deal with Eli Lilly for it?s underarm testosterone education, clinical practice, production of treatment Axiron and Mesoblast?s up to $2 pharmaceuticals and biotechology products. billion deal with Cephalon for it?s stem cell Members include Melbourne Health, University therapies. of Melbourne, Walter and Eliza Hall Institute of Medical Research, Howard Florey A recent industry survey showed that Neurosciences Institute and the Ludwig Australian biotechnology companies had 70 Institute for Cancer Research. clinical trials underway, with over half of these in either phase 2 or phase 3. Monash Health Research Precinct Based around Monash University this precinct Australia?s federal and state governments have links the university and the Southern targeted biotechnology as one of the innovative Healthcare network with major research industries that will be key to economic growth. organisation and infrastructure including As such the industry has been historically built CSIRO, the Australian Synchrotron and the on publically funded R&D including universities, Australian Stem Cell Centre. medical institutes and organisations such as CSIRO and compared with competing nations New South Wales Australia produces a larger proportion of Sydney is the traditional centre for lifescience graduates. pharmaceutical manufacture in Australia and a major proportion of global pharma companies There is still strong government support for and local generics companies are based here. biotechnology research, although as the sector These include Pfizer, Merck and AstraZeneca. matures governments are increasingly looking to fund projects particularly geared to New South Wales also hosts 120 biotechnology commercialisation. companies, is a major centre for clinical trials in Australia and also hosts major research Victoria institutes including the Garvan Institute for Victoria, and it?s state capital Melbourne, is the Medical Research, the Prince of Wales Medical largest centre for biotechnology in Australia. Comprising more of 140 companies, 13 major UK Trade & Investment Sector briefing: Biotechnology opportunities in AUSTRALIA Research Centre and the Westmead Millennium of metallic compounds using aqueous Institute. solutions. Queensland In total Western Australia is home to around The Queensland government has committed to 50 biotechnology companies. establishing the State as a centre of excellence in biotechnology that will employ over 16,000 South Australia people and generate $4 billion in revenues by South Australia currently supports around 40 2025. The government?s approach has been to biotechnology firms and again the state invest in infrastructure and promote integrated government is keen to increase the size of the translational research. sector. Most of the current organisations are housed in various precincts as with other Queensland?s biotechnology industry currently states, which are hoped to expand and provide comprises around 90 companies and 65 infrastructure and support. In South Australia research institutes with expertise in health and these are based in and around the capital medical biotechnology, drug discovery, clinical Adelaide and include: trials, tropical health and sub-tropical agricultural biotechnology. Florey Precinct Located in the CBD of Adelaide the Florey Since 1998 the Queensland government has Precinct is recognised for its life and medical invested over $600 million in the state?s sciences research. It is an intensive biotechnology industry to help fund a number concentration of health R&D capabilities in the of major institutes including; areas of biochemistry, genetics, microbiology, BioPharmaceuticals Australia manufacturing immunology and physiology ? a research facility, Institute for Molecular Bioscience, cluster renowned for discoveries in human Queensland Institute of Medical Research, reproductive medicine. Queensland Brain Institute, Australian Institute for Bioengineering and Nanotechnology, the Waite Research Institute Diamantina Institute for Cancer, Immunology The Waite Research Institute is the largest and Metabolic Medicine, the Mater Medical agricultural research institute in the Southern Research Institute and the Eskitis Institute for Hemisphere. It is co-located at the Waite Cell and Molecular Therapies. Campus with other companies and research institutes working on agricultural biotechnology Western Australia including, the Australian Centre for Plant Western Australia?s traditional strengths are in Functional Genomics, the FOODplus research the resources/mining and agriculture sectors, centre and the Wine Innovation Cluster. as such the biotechnology industry is focused largely on agricultural, industrial and Cooperative Research Centres environmental areas. That said, WA is also The Cooperative Research Centres (CRC) home to a number of leading human health program provides funding to build critical mass companies and research institutes. in research ventures between end-users and researchers which tackle major challenges. A Agricultural biotechnology research in WA CRC is an incorporated or un-incorporated focuses on a range of areas including molecular organisation formed through collaborative biology, genomics, proteomics for research on partnerships between publically funded plants, animals and microorganisms, researchers (i.e. University or Research floriculture, plant molecular markers, gene Institute) and at least one Australian end-user technology, crop biotechnology, rumen (private or public company or community biotechnology and microbial pathogens. organisation). Environmental and Industrial biotech R&D There are a total of 42 CRCs currently funded, covers areas such as biological processes for those with a biotechnology focus include: wastewater and sludge treatments, Asthma and Airways, Biomarker Translation, remediation of comtaminated land, renewable Cancer Therapeutics, Biomedical Imaging, energy biomass systems and bio-mining, Cancer Therapeutics, Oral Health, Vision, specifically in bioleaching and improving Hearing, Wound Management Innovation, Beef hydrometallurgical processes for the extraction Genetic Technologies and Invasive Animals. UK Trade & Investment Sector briefing: Biotechnology opportunities in AUSTRALIA Government Support The Australian Federal Government joins the state governments in providing incentives and programmes designed to assist the development of the biotechnology industry. Some of these are available to both local and international companies. In particular the R&D Tax Concession allows companies to deduct up to 175% of expenditure on R&D activities when lodging their corporate tax return. This is available to overseas companies running research programmes or clinical trials in Australia. Key Methods of Doing Business As a general rule Australian Biotechnology companies, along with the major research institutes will actively look to partner with overseas companies. The markets of the US and Europe are the key end target for Australian companies and they will particularly look for service providers with expertise in these markets to assist in the development of products. Ability and knowledge of ways to access funding, for example from the European Framework 7 programme can be a big incentive for Australian companies looking to outsource or collaborate on R&D programmes. Business culture is commonly face-to-face in Australia so meeting potential clients more than once is a must. Targeting meetings at international events such as BIO or BioPartnering Europe, followed up by visits to Australia is a useful way to generate a relationship. If you have any questions on the opportunities above, contact the UKTI] contacts named in this report. Business opportunities aimed specifically at UK companies are added daily to UKTI?s website. These leads are sourced by our staff overseas in British Embassies, High Commissions and Consulates, across all sectors and in over 100 markets. You can be alerted to business opportunities on a regular basis by registering on the UKTI website. Find out more on UKTI?s business opportunities service on the UKTI website UK Trade & Investment Sector briefing: Biotechnology opportunities in AUSTRALIA Major events and activities UKTI contacts AusBiotech 2011 Joe Dodd Trade & Investment Manager th th 16 -19 October 2011, Adelaide British-Consulate General, Melbourne Tel: +61 3 9652 1605 AusBiotech is the national biotechnology Email: industry organisation which also runs the annual AusBiotech conference, the largest biotechnology event in the Asia Pacific region. Shengul Kosyer Trade Promotion Officer In 2010 over 1500 participants attended the British-Consulate General, Melbourne conference in Melbourne including 200 Tel: +61 3 9652 1607 international delegates from 20 countries. Email: UK Trade & Investment supports UK companies wishing to attend AusBiotech by hosting on the UK stand, recommending companies to target through partnering and invitation to a high level networking event. Find full details of all events in this country and sector on the UKTI website. New export events are added daily to the site and you can register to be alerted to them on a daily, weekly or monthly basis UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events UK Trade & Investment Sector briefing: Biotechnology opportunities in AUSTRALIA Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for business in the Australia market are advised you to meet contacts and promote your to undertake as much market research and company in the Chinese market planning as possible in the UK. UKTI?s team in Australia, with its wide local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in global markets. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of agents/distributors work, or accessing other UKTI services and ? Key market players or potential specialist advice, please visit the UKTI website customers in the Chinese market to find contact details for your local UKTI ? Establishment of interest of such office. contacts in working with you Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2011 by UK Trade & Investment. Crown Copyright © UK Trade & Investment Sector briefing: Biotechnology opportunities in AUSTRALIA
Posted: 12 April 2011, last updated 12 April 2011

See more from Human Health Services in Australia

Expert Views    
Biotechnology Opportunities   By UK Trade & Investment
Healthcare Opportunities   By UK Trade & Investment
Hot Tips    
Chronic Disease in Australia   By U.S. Commercial Service Australia